Usage
  • 9 views
  • 9 downloads

Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer

  • Author / Creator
    Potts, Kyle G
  • Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent Bacillus Calmette-Guérin (BCG). BCG however, can be particularly dangerous for immunocompromised patients. Additionally, up to 40% of patients fail BCG therapy and cystectomy remains the standard treatment in these cases. This project examines whether vaccinia virus (VACV) can be used to treat preclinical models of NMIBC and in particular, bladder cancer that is refractory to BCG therapy. Here we have generated a novel oncolytic VACV by mutating the F4L gene that encodes the viral homolog of the stringently cell-cycle-regulated small subunit (RRM2) of ribonucleotide reductase. The F4L-deleted VACVs are highly attenuated in normal tissue and have a tropism that favors cancer cells commonly elevated in RRM2 levels, resulting in selective replication and tumor cell killing. VACVs efficiently replicate in BCGresistant and BCG-susceptible AY-27 cells. F4L-deleted VACVs selectively replicate in both the orthotopic AY-27 immunocompetent rat model and RT112-luc xenograft models, causing significant tumor regression or complete tumor ablation with no toxicity, while the commonly used ΔJ2R VACV causes significant toxicity in immunocompromised mice. Furthermore, rats cured of AY-27 tumors by VACV-treatment develop a protective anti-tumor immunity that is evident by tumor rejection upon challenge, as well as by ex vivo cytotoxic T-lymphocyte assays. Finally, the mutant VACVs replicate in both primary human bladder cancer cultures and tumor explants. Our findings demonstrate the enhanced safety and selectivity of our modified oncolytic VACV, making the F4L-deleted VACV a promising therapy for patients with BCG-refractory cancers and immune dysregulation.

  • Subjects / Keywords
  • Graduation date
    2017-11:Fall 2017
  • Type of Item
    Thesis
  • Degree
    Doctor of Philosophy
  • DOI
    https://doi.org/10.7939/R3N010727
  • License
    This thesis is made available by the University of Alberta Libraries with permission of the copyright owner solely for non-commercial purposes. This thesis, or any portion thereof, may not otherwise be copied or reproduced without the written consent of the copyright owner, except to the extent permitted by Canadian copyright law.
  • Language
    English
  • Institution
    University of Alberta
  • Degree level
    Doctoral
  • Department
    • Department of Oncology
  • Specialization
    • Experimental Oncology
  • Supervisor / co-supervisor and their department(s)
    • Hitt, Mary (Oncology)
    • Evans, David (Medical Microbiology and Immunology)
  • Examining committee members and their departments
    • Weinfeld, Michael (Oncology)
    • Moore, Ronald (Surgery)
    • Mossman, Karnen (Biochemistry)
    • Hitt, Mary (Oncology)
    • Evans, David (Medical Microbiology and Immunology)